|InterMune Inc (ITMN) Rises on Takeover Rumor|
Shares of InterMune Inc (NASDAQ:ITMN) were up around 10.8% on Mar 7 to end the day’s trading at $33.87, after reports from news agencies like Reuters and CNBC claimed that the company was attracting takeover interest from several pharmaceutical giants. InterMune Inc (NASDAQ:ITMN) has emerged as an attractive acquisition target after the...
valuewalk.com 6 hours ago
|InterMune Inc (ITMN) Rises on Takeover Rumor|
Shares of InterMune Inc (NASDAQ:ITMN) were up around 10.8% on Mar 7 to end the day’s trading at $33.87, after reports from news agencies like Reuters and CNBC claimed that the company was attracting takeover interest from several pharmaceutical giants. InterMune Inc (NASDAQ:ITMN) has emerged as an attractive acquisition target after the chances...
valuewalk.com 6 hours ago
|InterMune Rises on Takeover Rumor - Analyst Blog|
Shares of InterMune, Inc. (ITMN) were up around 10.8% on Mar 7 to end the day’s trading at $33.87, after reports from news agencies like Reuters and CNBC claimed that the company was attracting takeover interest from several pharmaceutical giants. InterMune has emerged as an attractive acquisition target after the chances of Esbriet (pirfenidone)...
zacks.com 8 hours ago
|Plavix Marketing Claims Kicked to West Virginia|
(CN) - Accused of falsely marketing Plavix as superior to aspirin to sell it for about 100 times more, Bristol-Myers Squibb and Sanofi-Aventis must in state court, a federal judge ruled. West Virginia Attorney General Darrell McGraw Jr. filed the complaint in the Circuit Court of Marshall County on Dec. 28, 2012, saying that the drugmakers...
courthousenews.com 12 hours ago
|Pharma-funded Military Consultants Say Military Suicides Not Caused By...|
OpEdNews – March 9, 2014 By Martha Rosenberg It took academic, government and military researchers five years to say they don’t really know what is causing military suicides but whatever it is–it isn’t the psychoactive drugs they are prescribing and pushing. There have been more than 6,500 suicides since the Iraq and Afghanistan wars says...
cchrint.org 12 hours ago
|10 Best Mid Cap Stocks To Invest In Right Now|
If you are looking for a semiconductor stock thats focus on an area thats not so cyclical, mid cap microcontroller (MCU) stock Atmel Corporation (NASDAQ: ATML) could be a good choice meaning its worth taking a closer look at the stock along with othermicrocontrollerplayers like Microchip Technology Inc (NASDAQ: MCHP), STMicroelectronics N.V. (NYSE:...
beststocks2016.com 12 hours ago
|Hot Medical Stocks For 2015|
Hot Medical Stocks For 2015: Galena Biopharma Inc (GALE) Galena Biopharma, Inc. (Galena), formerly RXi Pharmaceuticals Corporation, incorporated on April 3, 2006, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics. The Company is pursuing the...
top-stocks-investment-usa.blogspot.com 13 hours ago
|SEC Gets Split Verdict In Insider Trading Trail|
The SEC obtained a split verdict from a jury against two brothers in an insider trading case. Specifically, the Commission prevailed on Exchange Act Section 14(e) claims against each but lost its Section 10(b) claims. The case centered on a tender offer by French pharmaceutical company Sanofi-Aventis for Tennessee based drug distributor, Chattem,...
secactions.com 30 hours ago
|NIVOLUMAB - A PROMISING AGENT|
Emerging data on the immune therapy nivolumab (Bristol-Myers Squibb) "may allow medical oncologists to have raised expectations for patients with metastatic cancer," according to Geraldine O'Sullivan Coyne, MD, and colleagues from the National Cancer Institute, Bethesda, Maryland, in an editorial published this week. The essay accompanies a new...
cancerology.blogspot.com 45 hours ago
|Facebook Comment Change Revives Pharma Call for FDA Guidelines|
On Monday, Facebook began requiring pharmaceutical brand pages to enable comments, as expected. Yet, although pharma marketers are fearful of regulatory reaction to a potential flood of comments, some don’t see Facebook as the big villain in the story. It’s the Food and Drug Administration that’s raised the most ire. “Yesterday’s...
|Sanofi et. al. v. First Time US Generics|
Filed on : March 6, 2014 Type: Complaint for Patent Infringement Court : U.S. District Court for the District of Delaware Presided by: no judge yet assigned Civil Action No: 1:14-cv-00293-UNA Defendant(s) : 1. First Time US Generics Plaintiff(s) : Sanofi Sanofi-Aventis Morris, Nichols, Arsht & Tunnell LLP; Wilmington, DE Jack B. Blumenfeld Derek...
|Two guilty of insider trading in Sanofi deal|
A jury found two brothers guilty of using insider information to make an illicit $50,000 profit on the stock market in at least the eighth insider trading prosecution related to the 2010 purchase of a Chattanooga company by a French pharmaceutical giant. The U.S. Securities and Exchange Commission found that Andrew Jacobs passed secret information...
|Bristol-Myers Squibb sued over Plavix prescription drug|
Prescription drug manufacturers are facing suit over claims a prescription drug is dangerous. Richard Biby filed suit Jan. 25 in the Cook County Circuit Court against Bristol-Myers Squibb Co., Sanofi-Aventis US LLC, Sanofi-Aventis US Inc. and Sanofi-Synthelabo Inc., citing strict product liability, manufacturing defect, failure to warn and...
|An RNAi Therapeutic Could Be Last Man Standing in PCSK9|
PCSK9 has arguably become biotech’s hottest drug target as it promises to unlock much of the remaining unmet need in lowering ‘bad’ LDL cholesterol. While monoclonal antibodies have been the predominant and most advanced modality to address PCSK9 (e.g alirocumab Regeneron/Sanofi-Aventis and AMG145 by Amgen), RNAi Therapeutics have made...
|Florida Attorney General Pam Bondi Weekly Report to the People|
Volume 9, Issue 174 • March 7, 2014 PROTECTING FLORIDIANS | TEXT VERSION | EN ESPAÑOL Attorney General Bondi’s Weekly Briefing This week is National Consumer Protection Week, and I am dedicated to protecting Florida’s consumers. Floridians work hard to earn a living, and businesses work hard to remain profitable. Deceptive and unfair...
|Profit from Orphan Drugs: 3 Choices (Revised) - Analyst Blog|
Once given the moniker of orphans, drugs for rare diseases were originally considered to be an unviable proposition for pharma companies. This was because the number of patients for treatments was so small that their development and production were considered to be an unviable proposition. Today, they have emerged as major money spinners for the...
|Treating dengue more difficult with growing obesity: experts|
By Tan Ee Lyn SINGAPORE | Fri Dec 3, 2010 9:08am EST SINGAPORE (Reuters) – Experts warned Friday that treating dengue, a potentially fatal disease caused by a mosquito-borne virus, will become more difficult in the future as more people around the world become overweight and obese. Dengue patients suffer from capillary permeability, when fluid...
|Genzyme Corp. settles allegations of off-label marketing|
Wisconsin has joined with other states and the federal government to settle allegations that Genzyme Corp. (Genzyme) marketed and caused false claims to be submitted to federal and state health care programs for use of a “slurry” version of its Seprafilm adhesion barrier. Seprafilm is a thin film intended to reduce adhesions after surgery by...
|Multaq: Increased Risks Of Side Effects, Including Death, Outweigh Any...|
In Addition, They Are Highly Critical Of Relationship The Sanofi Aventis Drug Company Had With Those Doctors Who Developed Prescribing Guidelines (Posted by Tom Lamb at DrugInjuryWatch.com) As we know, now, since being approved by the FDA in 2009 and soon becoming an often-prescribed atrial fibrillation drug, Multaq has been associated with...
|Genzyme to pay $22M to resolve False Claims Act lawsuit|
Bondi TALLAHASSEE, Fla. (Legal Newsline) – Florida Attorney General Pam Bondi announced a $22.28 million multi-state and federal settlement on Tuesday with a Massachusetts-based biotechnology company that allegedly caused hospitals to submit false Medicaid claims. Genzyme Corp., a Cambridge, Mass.-based company that was acquired by Sanofi-Aventis...
|EVA Dimensions Upgrades Sanofi-Aventis to Hold (SNY)|
EVA Dimensions upgraded shares of Sanofi-Aventis (NYSE:SNY) from an underweight rating to a hold rating in a research report released on Tuesday morning, StockRatingsNetwork reports. Several other analysts have also recently commented on the stock. Analysts at Sanford C. Bernstein cut their price target on shares of Sanofi-Aventis from $57.00 to...
|Profit from Orphan Drugs: 3 Choices - Analyst Blog|
Once given the moniker of orphans, drugs for rare diseases were originally considered to be an unviable proposition for pharma companies. This was because the number of patients for treatments was so small that their development and production were considered negligible. Today, they have emerged as major money earners for the pharma sector. What...
|Process Wednesday: photooxidation to get industrial scale artemisinin|
Credit: OPRD, Turconi et al. From the pages of Organic Process Research and Development , a fascinating article by workers at Sanofi-Aventis talking about their industrial route to the anti-malarial artemisinin. They decided to use a photooxidation to perform the semi-synthesis of the material and here, they talk a little about the challenges:...
|To access Twitter data for real time monitoring, please contact us